echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Retroviral Delivery and Anti-HIV Testing of Hammerhead Ribozymes

    Retroviral Delivery and Anti-HIV Testing of Hammerhead Ribozymes

    • Last Update: 2020-11-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Successful ribozyme-mediated gene therapy for HIV infection has to take into account several factors:
    1. 
    The therapeutic gene must interfere with or shut down the expression of essential viral genes.
    2. 
    This requires a vector system for gene delivery and expression in HIV-sensitive cells.
    3. 
    To bypass the high genetic variability of the HIV-1 replication process, the target sequence should be chosen in highly conserved sequences of HIV-1. These fortunately are mostly present in the essential regulatory genes (tat, rev ) or sequences (PBS, U5), which are required to produce infectious viral particles (1 ).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.